Commonwealth Equity Services’s Amylyx Pharmaceuticals AMLX Stock Holding History

Commonwealth Equity Services’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$590K	Buy	+20,291	New	+$538K	﹤0.01%	3103

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Commonwealth Equity Services's AMLX Position: Q3 2026 in Review

Commonwealth Equity Services opened a new position in Amylyx Pharmaceuticals (AMLX) in Q3 2026: 20,291 shares worth $590K. The stake represents ﹤0.01% of the portfolio and ranks #3103 among its holdings.

147 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.

Commonwealth Equity Services held 20,291 shares of Amylyx Pharmaceuticals worth $590K as of Q3 2026.
Amylyx Pharmaceuticals was a new Commonwealth Equity Services position in Q3 2026.
Amylyx Pharmaceuticals made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q3 2026, its #3103 holding.
147 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.

Based on Commonwealth Equity Services's 13F filing for Q3 2026, filed 2 Nov 2026.